Tuesday, October 18, 2016| aflibercept, Carl Zeiss Meditec, FDA Approval/Clearance, Ocular Therapeutix, Regeneron Pharmaceuticals, ReLEx SMILE, VisuMax femtosecond laser, Wet AMD

EyewireTV — Breaking Industry News Live from the AAO Meeting in Chicago

In this week’s EyewireTV, Ocular Therapeutix enters into a strategic collaboration with Regeneron Pharmaceuticals to develop a sustained-release formulation of aflibercept (Eylea) for the treatment of wet AMD and other retinal diseases; and Carl Zeiss Meditec showcases its VisuMax Femtosecond Laser ReLEx SMILE procedure for the first time since FDA approval last month.

Watch Video

Wednesday, October 12, 2016| Abbott Medical Optics, AMO, Anterior Segment, Astigmatism, Bausch+Lomb, Choroidal Neovascularization, CNV, Genentech, Pachymetry, Ranibizumab, Tecnis Toric IOL

EyewireTV - Lucentis for Myopic CNV; New B+L Topographer

In this week’s, the FDA accepts Genentech’s supplemental biologics license application and grants priority review for Lucentis (ranibizumab) for the treatment of myopic choroidal neovascularization; and Bausch + Lomb introduces the Orbscan 3 anterior segment analyzer, which offers surgeons the ability to examine anterior and posterior astigmatism and optical pachymetry. Also, Abbott releases the Tecnis toric calculator with posterior corneal astigmatism compensations.

Watch Video

Wednesday, October 05, 2016| Acquisitions, Mergers, Clinical Trials, Corneal Collagen Crosslinking, CXL, FDA Approval/Clearance, Katena Products, Regeneron Pharmaceuticals, Surgical Instruments, Wet AMD

EyewireTV — CXL Now Performed in US; Wet AMD Candidate Fails Trial

In this week’s EyewireTV, the first FDA-approved cross-linking procedures are now being performed in the United States; and in a mid-stage trial, Regeneron's combination therapy shows no benefit over Eylea alone for the treatment of wet AMD. Also, Katena Products, a provider of ophthalmic instruments, biologics, and devices, acquires ophthalmic instrument maker Eagle Vision.

Watch Video

Wednesday, September 28, 2016| Cataract Surgery, FDA Approval/Clearance, Glaucoma, Glaukos Corporation, Heidelberg Engineering, iStent, LASIK

EyewireTV — Long-Term LASIK Data; New iStent Studies

In this week’s EyewireTV, findings from a scientific literature review of more than 4,400 peer-reviewed clinical studies of LASIK over a 7-year period show the procedure is among the safest and most effective elective procedures available; and two studies support the effectiveness of the Glaukos iStent Trabecular Micro-Bypass both as a standalone procedure and when used in conjunction with cataract surgery. Also, Heidelberg Engineering receives FDA 510(k) clearance to market the Spectralis OCT Glaucoma Module Premium Edition in the United States.

Watch Video

Wednesday, September 21, 2016| Abbott Medical Optics, AMO, Acquisitions, Mergers, Aerie Pharmaceuticals, Clinical Trials, Glaucoma, Johnson & Johnson Vision Care, Myopia

EyewireTV — J&J Buys AMO; FDA Approves SMILE Procedure

In this week’s EyewireTV, in a major acquisition that will reshape the ophthalmic landscape, Johnson & Johnson agrees to acquire Abbott Medical Optics for about $4.3 billion in cash; and ophthalmologists in the United States will have an entirely new option in the surgical treatment of myopia as the FDA approves the ReLEx SMILE vision correction procedure. Also, Aerie Pharmaceuticals reports positive 90-day primary efficacy results of its phase 3 clinical trial (Mercury 1) for glaucoma candidate Roclatan.

Watch Video

Wednesday, September 14, 2016| Alcon, Carl Zeiss Meditec, FDA Approval/Clearance, IOL Implantation, Microincision Cataract Surgery, MICS, Myopia, Rayner Intraocular Lenses, ReLEx SMILE, VisuMax femtosecond laser

EyewireTV - Breaking Industry News from the EURETINA/ESCRS Meetings in Copenhagen

In this week’s EyewireTV, Carl Zeiss Meditec receives FDA approval of the VisuMax Femtosecond Laser ReLEx SMILE procedure, providing ophthalmologists in the United States an entirely new option in the surgical treatment of myopia; and Alcon launches a new visualization system for digitally assisted vitreoretinal surgery called the NGENUITY 3D. Also, Rayner releases its RayOne preloaded IOL injection system, which consists of a new microincision cataract surgery (MICS) lens and fully preloaded IOL injection system.

Watch Video

Wednesday, September 07, 2016| Acquisitions, Mergers, Allergan, Contact Lenses & Solutions, Glaucoma, RetroSense Therapeutics

EyewireTV — Allergan CEO Pledges Responsible Pricing; Contact Lens for Glaucoma

In this week’s EyewireTV, Allergan adds another clinical-stage biotech company to its portfolio after acquiring gene therapy company RetroSense Therapeutics; and in a blog post, Allergan President and CEO Brent Saunders pledges to put limits on the size and frequency of drug price hikes. Also, a contact lens designed to deliver medication could improve outcomes for patients with glaucoma and other conditions requiring treatment with eye drops.

Watch Video

Wednesday, August 31, 2016| Dry Eye, FDA Approval/Clearance, Meibomian Gland Dysfunction, MGD, Shire, TearScience

EyewireTV — US Commercial Launch of the Raindrop Inlay; Xiidra Now Available

In this week’s EyewireTV, the first commercial implantations of the Raindrop Near Vision Inlay are performed at the Slade & Baker Vision Center in Houston; and 6 weeks after receiving approval from the FDA, Shire's dry eye drug Xiidra (lifitegrast ophthalmic solution 5%) is now available by prescription in the United States. Also, a new study shows that a single TearScience LipiFlow treatment can deliver sustained mean improvement in meibomian gland function and dry eye symptoms through 12 months.

Watch Video

Wednesday, August 24, 2016| Antibiotics, Auven Therapeutics, Dry Eye, Intravitreal Injection, Technology

EyewireTV — Dry Eye Drug Candidate Advances; Topical Antibiotics Study

In this week’s EyewireTV, Auven Therapeutics completes patient enrollment in a phase 3 confirmatory study of its dry eye disease drug candidate Seciera (OTX-101); and new research shows that topical antibiotics may be unnecessary in patients receiving intravitreous injections when povidone-iodine is used to prevent endophthalmitis. Also, a new vision simulator could help patients see how the world would look with each type of IOL before they have surgery.

Watch Video

Wednesday, August 17, 2016| Age-Related Macular Degeneration, Allergan, Cataract Surgery, Drug Delivery, ForSight Vision, Glaucoma, Research

EyewireTV — Interview with Allergan Executives; DED Reading Study

In this week’s EyewireTV, Allergan expands its glaucoma portfolio after agreeing to purchase ForSight Vision5, the maker of a noninvasive drug delivery platform; and a large study suggests that cataract surgery may have no clear link with the incidence of progression of age-related macular degeneration. In the feature, Allergan President and CEO Brent Saunders and Chief Commercial Officer Bill Meury talk to EyewireTV about a variety of topics, including the company’s research and development strategy, an update on its eye care pipeline, and the future of Restasis amid new competition.

Watch Video

Wednesday, August 10, 2016

EyewireTV – LASIK Satisfaction Study; Office-Based Cataract Surgery

In this week's EyewireTV, a large study finds that contact lens users who chose to have LASIK were more satisfied with their vision a year after the surgery ­ and remain satisfied over time; and ThromboGenics announces the 2-year results of the OASIS study evaluating the efficacy and safety of Jetrea (ocriplasmin) in patients symptomatic vitreomacular adhesion. Also, leading ophthalmologists share their opinions on the growing trend of performing office-based cataract surgery.

Watch Video

Wednesday, August 03, 2016| Alcon, CyPass Micro-Stent, FDA Approval/Clearance, Glaucoma, Macular Degeneration, Pixium Vision, Spectral-domain OCT, SD-OCT, Topcon Medical Systems

EyewireTV — FDA Approves MIGS Device; New OCT Technology in the US

In this week’s EyewireTV, the FDA approves Alcon's CyPass Micro-Stent system, a minimally invasive glaucoma surgical device for use in combination with cataract surgery; and Topcon Medical Systems receives FDA clearance for the 3D OCT-1 Maestro, which combines a high-resolution, color, nonmydriatic retinal camera with the latest spectral-domain OCT technology. Also, Pixium Vision receives the CE mark for its IRIS II bionic vision system, indicated for people with vision loss from outer retinal degeneration.

Watch Video

Wednesday, July 27, 2016| AcuFocus, Argus II Retinal Prosthesis System, Carl Zeiss Meditec, FDA Approval/Clearance, Ocular Therapeutix, Retinitis pigmentosa, Valeant

EyewireTV – Manufacturing Issues Stall Two Ophthalmic Drugs; New Leaders at Zeiss and AcuFocus

In this week's EyewireTV, citing manufacturing deficiencies, the FDA decides not to approve the new drug applications of two ophthalmic agents, Valeant Pharmaceuticals’ Vesneo (latanoprostene bunod ophthalmic solution 0.024%) and Ocular Therapeuitix’s Dextenza (dexamethasone insert 0.4 mg); and 5-year study results of the Argus II retinal prosthesis system indicate the device remains safe and beneficial for patients blind from retinitis pigmentosa. Also, James Mazzo is leaving AcuFocus, where he is chairman and CEO, to serve as the Global President of Ophthalmology at Carl Zeiss Meditec, and Alan Waterhouse is named the new President and Chief Operating Officer of AcuFocus.

Watch Video

Wednesday, July 20, 2016| Abbott Medical Optics, AMO, Allergan, Avedro, Cornea, Corneal Collagen Crosslinking, CXL, Corneal Ectasia, Dry Eye, FDA Approval/Clearance, Refractive Surgery, Tecnis Symfony IOL

EyewireTV - Tecnis Symfony IOL FDA Approved; New Cross-Linking Indication in US

In this week’s EyewireTV, the FDA approves Abbott’s Tecnis Symfony and Tecnis Symfony Toric IOLs, which the company says are the first extended depth of focus IOLs; and Avedro receives FDA approval for a second indication for its corneal collagen cross-linking platform—the treatment of corneal ectasia following refractive surgery. Also, Allergan files a de novo application with the FDA for the Oculeve Intranasal Tear Neurostimulator device, which is being investigated for temporarily increasing tear production upon activation in patients with dry eye disease.

Watch Video

Wednesday, July 13, 2016| Contact Lenses & Solutions, CooperVision, Dry Eye, FDA Approval/Clearance, Shire

EyewireTV - FDA Approves Xiidra (Lifitegrast) Dry Eye Treatment; CMS Reimbursement Rates

In this week’s EyewireTV, Shire receives FDA approval for its blockbuster dry eye treatment Xiidra (lifitegrast ophthalmic solution 5%), the only prescription eye drop indicated for the treatment of both the signs and symptoms of dry eye disease; and the Centers for Medicare and Medicaid Services issues its proposed calendar year 2017 payment rate regulation for hospital outpatient departments and ambulatory surgery centers. Also, CooperVision introduces Biofinity Energys, the first contact lenses specifically designed for digital device users.

Watch Video
Load More